Gmt Capital Corp Dynavax Technologies Corp Transaction History

Gmt Capital Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$11.85 - $16.0 $13.7 Million - $18.5 Million	-1,158,337 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$15.15 - $20.75 $15.9 Million - $21.8 Million	-1,052,500 Reduced 47.61%	1,158,337 $17.7 Million
Q1 2018 May 15, 2018	SELL	$14.65 - $19.9 $11.1 Million - $15.1 Million	-756,800 Reduced 25.5%	2,210,837 $43.9 Million
Q4 2017 Feb 12, 2018	SELL	$17.3 - $24.08 $1.55 Million - $2.16 Million	-89,800 Reduced 2.94%	2,967,637 $55.5 Million
Q3 2017 Nov 09, 2017	BUY	$15.2 - $21.5 $794,960 - $1.12 Million	52,300 Added 1.74%	3,057,437 $65.7 Million
Q2 2017 Aug 14, 2017	BUY	N/A	3,005,137	3,005,137 $29.5 Million

257

132M

371K

99.2K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.44B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Gmt Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Gmt Capital Corp with notifications on news.